Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) released its earnings results on Thursday. The biopharmaceutical company reported ($0.41) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.76) by $0.35, Bloomberg Earnings reports. During the same period in the prior year, the firm earned ($0.12) EPS.

Sunesis Pharmaceuticals (NASDAQ SNSS) traded down 2.23% during midday trading on Thursday, hitting $2.63. The stock had a trading volume of 80,555 shares. The firm has a 50 day moving average of $2.78 and a 200 day moving average of $3.55. The firm’s market cap is $56.44 million. Sunesis Pharmaceuticals has a 52 week low of $2.51 and a 52 week high of $6.30.

A number of equities research analysts have recently commented on SNSS shares. Cantor Fitzgerald reiterated a “hold” rating and set a $3.00 target price on shares of Sunesis Pharmaceuticals in a research note on Tuesday, May 2nd. Zacks Investment Research cut Sunesis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, June 28th.

TRADEMARK VIOLATION WARNING: “Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Posts Earnings Results, Beats Expectations By $0.35 EPS” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another site, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The legal version of this story can be viewed at

Large investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC boosted its stake in Sunesis Pharmaceuticals by 1.1% in the first quarter. Renaissance Technologies LLC now owns 111,811 shares of the biopharmaceutical company’s stock valued at $458,000 after buying an additional 1,230 shares during the period. Neuberger Berman Group LLC boosted its stake in Sunesis Pharmaceuticals by 16.6% in the first quarter. Neuberger Berman Group LLC now owns 140,555 shares of the biopharmaceutical company’s stock valued at $576,000 after buying an additional 20,000 shares during the period. Finally, TFS Capital LLC acquired a new stake in Sunesis Pharmaceuticals during the first quarter valued at approximately $158,000. 55.15% of the stock is currently owned by institutional investors.

Sunesis Pharmaceuticals Company Profile

Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).

Earnings History for Sunesis Pharmaceuticals (NASDAQ:SNSS)

Receive News & Ratings for Sunesis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.